Functional Analysis of the Arg91GIn Substitution in the Factor VIII Binding Domain of von Willebrand Factor Demonstrates Variable Phenotypic Expression

Summary

An Arg91Gln substitution in the mature von Willebrand factor (vWF) has been associated with defective binding of vWF to factor VIII (FVIII). We studied four families with members initially classified as having type I von Willebrand disease (vWD) who were either homozygous or heterozygous for the Arg91Gln change. The first family was the original case described by Nishino et al. (1) where three members were homozygous for the Gln91 allele. They had a low FVIII coagulant activity:vWF antigen (VIIIC:vWFAg) ratio, from 0.29 to 0.44, and the ability of their plasma vWF to bind FVIII was markedly decreased. All the heterozygous members had normal vWF and FVIII levels but the capacity of their plasma vWF to bind FVIII was reduced and intermediate between the homozygous members and normals. The affected individual from the second family was heterozygous for the Gln91 allele and demonstrated a VIIIC:vWFAg ratio of 0.98. The FVIII binding assay confirmed the heterozygous status indicating that the moderately low levels of vWF were due to reduced expression of both alleles. The propositus from the third family was also heterozygous and had below normal levels of vWF as well as a low VIIIC:vWFAg ratio of 0.34; however, FVIII binding to her plasma vWF was similar to that of the homozygous individuals suggesting that Gln91-vWF was the major circulating form. Her daughter who has type I vWD inherited the allele without the Gln91 mutation indicating that the expression of this allele was indeed impaired. The heterozygous patient in the fourth family had a vWF level of 24 U/dl but an VIIIC:vWFAg ratio greater than 2. Her plasma vWF showed normal FVIII binding implying that the Gln91 mutation was linked to a defect that repressed the expression of the allele. The Arg91Gln substitution appears to decrease but not eradicate FVIII binding suggesting a critical concentration of vWF be attained before the defect becomes phenotypically important.

• References

• 1 Nishino M, Girma JP, Rothschild C, Fresssinaud E, Meyer D. New variant of von Willebrand disease with defective binding to factor VIII. Blood 1989; 74: 1591-1599
• 2 Ruggeri ZM, Ware J. The structure and function of von Willebrand factor. Thromb Haemostas 1992; 67: 594-599
• 3 Weiss HJ, Sussman I, Hoyer W. Stabilization of factor VIII in plasma by the von Willebrand factor. Studies on posttransfusion and dissociated factor VIII and in patients with von Willebrand’s disease. J Clin Invest 1977; 60: 390-404
• 4 Tuddenham EGD, Lane RS, Rotblat F, Johnson AJ, Snape TJ, Middleton S, Kernoff PBA. Response to infusions of polyelectrolyte fractionated human factor VIII concentrate in human haemophilia A and von Willebrand’s disease. Br J Haematol 1982; 52: 259-267
• 5 Koedam KA, Hamer RJ, Beeser-Visser NH, Bouma BN, Sixma JJ. The effect of von Willebrand factor on activation of factor VIII by factor Xa. Eur J Biochem 1990; 189: 229-234
• 6 Koedam JA, Meijers JCM, Sixma JJ, Bouma BN. Inactivation of human factor VIII by activated protein C. J Clin Invest 1988; 82: 1236-1243
• 7 Andersson L-O, Brown JE. Interaction of factor VIII-von Willebrand factor with phospholipid vesicles. Biochem J 1981; 200: 161-167
• 8 Fay PJ, Coumans JV, Walker FJ. Von Willebrand factor mediates protection of factor VIII from activated protein C-catalyzed inactivation. J Biol Chem 1991; 266: 2172-2177
• 9 Fay PJ. Reconstitution of human factor VIII from isolated subunits. Arch Biochem Biophys 1988; 262: 525-531
• 10 Kaufman RJ, Wasley LC, Dorner AJ. Synthesis, processing, and secretion of recombinant human factor VIII expressed in mammalian cells. J Biol Chem 1988; 263: 6352-6362
• 11 Wise RJ, Dorner AJ, Krane M, Pittman DD, Kaufman RJ. The role of von Willebrand factor multimers and propeptide cleavage in binding and stabilization of factor VIII. J Biol Chem 1991; 266: 21948-21955
• 12 Foster PA, Fulcher CA, Marti T, Titani K, Zimmerman TS. A major factor VIII binding domain resides within the amino-terminal 272 amino acid residues of von Willebrand factor. Zimmerman TS. J Biol Chem 1987; 262: 8443-8446
• 13 Takahashi Y, Kalafatis M, Girma JP, Serwin K, Andersson LO, Meyer D. Localization of a factor VIII binding domain on a 34 kDa fragment of the N-terminal portion of von Willebrand factor. Blood 1987; 70: 1679-1682
• 14 Bahou WF, Ginsburg D, Sikkink R, Litwiller R, Fass DN. A monoclonal antibody to von Willebrand factor (vWF) inhibits factor VIII binding. Localization of its antigenic determinant to a nonadecapeptide at the amino terminus of the mature vWF polypep-tide. J Clin Invest 1989; 84: 56-61
• 15 Mazurier C, Dieval J, Jorieux S, Delobel J, Goudemand M. A new von Willebrand factor defect in a patient with factor VIII deficiency but with normal levels and multimeric patterns of both plasma and platelet vWF. Characterization of abnormal vWF/FVIII interaction. Blood 1990; 75: 20-6
• 16 Mazurier C, Gaucher C, Jorieux S, Parquet-Gernez A, Goudemand M. Evidence for a von Willebrand factor defect in factor VIII binding in three members of a family previously misdiagnosed mild haemophilia A and haemophilia A carriers: consequences for therapy and genetic counselling. Br J Haematol 1990; 76: 372-379
• 17 Kroner PA, Friedman KD, Fahs SA, Scott JP, Montgomery RR. Abnormal binding of factor VIII is linked with the substitution of glutamine for arginine 91 in von Willebrand factor in a variant form of von Willebrand disease. J Biol Chem 1991; 266: 19146-19149
• 18 Cacheris PM, Nichols WC, Ginsburg D. Molecular characterization of unique von Willebrand disease variant. J Biol Chem 1991; 266: 13499-13502
• 19 Ginsburg D, Sadler JE. Von Willebrand disease: a database of point mutations, insertions and deletions. Thromb Haemostas 1993; 69: 177-184
• 20 Kroner PA, Fahs SA, Vokac EA, Friedman KD, Montgomery RR. Novel missense mutations in von Willebrand factor (vWF) associated with defective vWF/factor VIII interaction in a patient with type I von Willebrand disease. Blood (Suppl. 01) 1991; 78: 178a
• 21 Jorieux S, Tuley EA, Gaucher C, Mazurier C, Sadler JE. The mutation Arg (53) → Trp causes von Willebrand disease Normandy by abolishing binding to factor VIII. Studies with recombinant von Willebrand factor. Blood 1992; 79: 563-567
• 22 Tuley EA, Gaucher C, Jorieux S, Worrall NK, Sadler JE, Mazurier C. Expression of von Willebrand factor “Normandy”: An autosomal mutation that mimics hemophilia A. Proc Natl Acad Sci USA 1991; 88: 6377-6381
• 23 Peerlinck K, Eikenboom JCJ, Ploos Van Amstel HK, Sangtawesin W, Arnout J, Reitsma PH, Vermylen J, Briët E. A patient with von Willebrand‗s disease characterized by a compound heterozygosity for a substitution of Arg⁸⁵⁴ by Gin in the putative factor-VIII-binding domain of von Willebrand factor (vWF) on one allele and very low levels of mRNA from the second vWF allele. Br J Haematol 1992; 80: 358-363
• 24 Ruggeri ZM, Zimmerman TS. Von Willebrand factor and von Willebrand disease. Blood 1987; 70: 895-904
• 25 Mielke CH, Kaneshire MM, Maher IA, Weiner JM, Rapaport SI. The standardized normal Ivy bleeding time and its Prolongation by aspirin. Blood 1969; 34: 204-215
• 26 Meyer D, Obert B, Pietu G, Lavergne JM, Zimmerman TS. Multimeric structure of factor VIII/von Willebrand factor in von Willebrand‗s disease. J Lab Clin Med 1980; 95: 590-602
• 27 Saiki RK, Gelfand DH, Stoffel S, Scharf SJ, Higuchi R, Horn GT, Mullis KB, Erlich HA. Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science 1988; 239: 487-491
• 28 Ribba AS, Lavergne JM, Bahnak BR, Derlon A, Pietu G, Meyer D. Duplication of methionine within the glycoprotein Ib binding domain of von Willebrand factor detected by denaturing gradient gel electrophoresis in a patient with type IIB von Willebrand disease. Blood 1991; 78: 1738-1743
• 29 Mancuso DJ, Tuley EA, Westfield LA, Worrall NK, Shelton-Inloes BB, Sorace JM, Alevy TG, Sadler JE. Structure of the gene for human von Willebrand factor. J Biol Chem 1989; 264: 19514-19527
• 30 Sadler JE, Ginsburg D. A database of polymorphisms in the von Willebrand factor gene and pseudogene. Thromb Haemostas 1993; 69: 185-191
• 31 Bahnak BR, Lavergne JM, Ferreira V, Keribirou-Nabias D, Meyer D. Comparison of the primary structure of the functional domains of human and porcine von Willebrand factor that mediate platelet adhesion. Biochem Biophys Res Commun 1992; 182: 561-568
• 32 Cox Gill, Endres-Brooks J, Bauer PJ, Marks WJ, Montgomery RR. The effect of AB0 blood group on the diagnoses of von Willebrand disease. Blood 1987; 69: 1691-1695
• 33 Lollar P, Parker CG. Stochiometry of the porcine factor VIII-von Willebrand factor association. J Biol Chem 1987; 262: 17572-17576